Novo Nordisk in the present day introduced the presentation of 34 abstracts highlighting the breadth of its portfolio on the upcoming 84th Scientific Classes of the American Diabetes Affiliation (ADA). The convention shall be held in-person and just about from 21–24 June 2024 in Orlando, US.
Further information from three landmark trials with semaglutide may even be offered in devoted scientific periods. The trials assess extra potential advantages of semaglutide, together with analysis of kidney and cardiovascular endpoints in folks with sort 2 diabetes and power kidney illness (FLOW, semaglutide 1.0 mg) and cardiovascular and glucose-related endpoints in folks with weight problems and CVD, with and with out diabetes (SELECT and STEP HFpEF, semaglutide 2.4 mg).
We acknowledge that cardiometabolic circumstances like heart problems, power kidney illness, weight problems and kind 2 diabetes are sometimes interlinked and would possibly happen in the identical affected person. We have to develop medicines that tackle a number of sides of the ailments. The broad information being offered this yr at ADA mirror this objective. Particularly, information from FLOW and SELECT take a look at methods to deal with widespread comorbidities of diabetes and weight problems, corresponding to kidney illness and heart problems.”
Stephen Gough, senior vp and international chief medical officer, Novo Nordisk
All abstracts shall be revealed on the web site of the journal Diabetes®. Information from the scientific periods shall be made obtainable after their presentation.
Abstract of displays
Scientific periods
The next information shall be offered within the devoted scientific periods as part of the scientific agenda of the congress:
| The primary devoted kidney end result trial with a GLP1-RA once-weekly semaglutide – FLOW trial outcomes (scientific session; 24 June, 13:30–15:00 EST) |
| SELECT trial – New appears at glycemia, irritation, and coronary heart failure (scientific session; 22 June, 08:00–09:00 EST) |
| The STEP-HFpEF and STEP-HFpEF-DM trials – Concentrating on weight problems to deal with coronary heart failure (scientific session; 23 June, 16:30–18:00 EST) |
Poster and oral displays
The next abstracts had been submitted by Novo Nordisk and are accepted for presentation on the congress:
| Diabetes |
| Ozempic® (once-weekly semaglutide 1.0 mg) |
- Comparative effectiveness of semaglutide in T2D – yr 2 outcomes of a randomized pragmatic medical trial (230-OR)
|
- Lengthy-term effectiveness related to upkeep doses of once-weekly semaglutide in US adults with poorly managed T2D (766-P)
|
- Semaglutide in sufferers with peripheral arterial illness and kind 2 diabetes: comorbidities and concomitant drugs from the STRIDE trial (784-P)
|
- Actual-world influence of once-weekly injectable semaglutide on weight, BMI and HbA1c outcomes in sort 2 diabetes: an observational examine (PAUSE) (857-P)
|
- Actual-World Impression of As soon as-Weekly Injectable Semaglutide (sema OW) vs. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Well being Care Useful resource Utilization (HCRU) Outcomes in Sort 2 Diabetes (T2D) – An Observational Research (PAUSE) (1884-LB)
|
| Rybelsus® (once-daily oral semaglutide) |
- Evaluating the efficacy of oral semaglutide in Chinese language sufferers with T2D by baseline traits: submit hoc evaluation of PIONEER 11 and 12 (752-P)
|
- Actual-world influence of fasting on adherence to dosing directions and efficacy of oral semaglutide throughout Ramadan in folks with sort 2 diabetes: O-SEMA-Quick sub-analysis (808-P)
|
| CagriSema |
- CagriSema improves insulin sensitivity in diet-induced overweight rats (763-P)
|
| As soon as-weekly insulin icodec |
- Healthcare useful resource utilization and prices with well timed vs delayed basal insulin initiation (816-P)
|
- Demographic, medical, and therapy traits of sufferers with well timed vs. delayed basal insulin initiation (817-P)
|
- No proof of elevated bodily activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T1D: ONWARDS 6 (824-P)
|
- Efficacy and security of once-weekly insulin icodec versus once-daily basal insulin in people with T2D by kidney operate: ONWARDS 1–5 (826-P)
|
- No proof of elevated bodily activity-related hypoglycemia with once-weekly insulin icodec versus once-daily basal insulin in T2D: ONWARDS 1-5 (830-P)
|
- Adherence to app-based dose steerage for once-weekly insulin icodec in insulin-naive T2D: submit hoc evaluation of ONWARDS 5 (836-P)
|
- Impression of age on the efficacy and security of once-weekly insulin icodec versus once-daily insulin in T2D (ONWARDS 1–5) (838-P)
|
- Efficacy and security of once-weekly insulin icodec versus once-daily basal insulin in sort 2 diabetes in accordance with baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1–5 (840-P)
|
- Efficacy and security of once-weekly insulin icodec vs once-daily basal insulin in T2D by ethnicity and race: ONWARDS 1–5 (841-P)
|
- Value-effectiveness of insulin icodec for the therapy of sort 2 diabetes in Canada (1046-P)
|
- Efficacy and security outcomes with once-weekly insulin icodec versus once-daily insulin degludec in T1D in accordance with glycemic variability: ONWARDS 6 submit hoc evaluation (1882-LB)
|
| Day by day insulins |
- Affect of the functionally selective insulin analog NNC-965 on cardiac construction and performance versus insulin glargine (IGla) (822-P)
|
- Improved glycemic management in folks with sort 2 diabetes (T2D) initiating or switching to insulin degludec/insulin aspart (IDegAsp) in a real-world setting in China (publication solely)
|
| Basic diabetes |
- Persistence and adherence of as soon as weekly GLP-1 receptor agonists in sufferers with sort 2 diabetes and atherosclerotic heart problems in a real-world setting (740-P)
|
- Impression of newer GLP-1 RAs on HbA1c in US adults with sort 2 diabetes: a population-level time-series evaluation (774-P)
|
- Understanding attitudes about basal insulin: insights from a worldwide survey of individuals with sort 2 diabetes (833-P)
|
|
|
- Prevalence of atherosclerotic cardiovascular ailments in adults with sort 2 diabetes in Jordan: the PACT-MEA Research (1789-LB)
|
- In vivo chain-splitting of human insulin (2032-LB)
|
| Digital Well being |
- Enchancment in time in vary after sensible insulin pen initiation in Austria (842-P)
|
- Multinational evaluation of things related to missed bolus insulin injections utilizing sensible pen information (843-P)
|
| Weight problems |
| Wegovy® (once-weekly semaglutide 2.4 mg) |
- CONCRETE – characterization of sufferers receiving telemedicine and branded antiobesity treatment for medical weight administration: a retrospective evaluation (1684-P)
|
- Scientific outcomes in sufferers with weight problems or obese handled with semaglutide 2.4 mg: a real-world retrospective cohort examine in america (SCOPE 2) (1691-P)
|
- Modeling the Impression of Semaglutide 2.4 mg in U.S. Sufferers with Atherosclerotic Cardiovascular Illness and BMI ≥27 kg/m2 (1981-LB)
|
| Basic weight problems |
- Affected person-centered weight administration medical determination assist: a proof-of-concept examine (1101-P)
|
- Prevalence, traits, and medical burden amongst sufferers with obese or weight problems and established ASCVD in a US actual world setting (1692-P)
|
About Ozempic®
As soon as-weekly subcutaneous semaglutide is accepted in 0.5 mg, 1.0 mg and a couple of.0 mg doses underneath the model title Ozempic® and indicated as an adjunct to weight-reduction plan and train to enhance glycemic management in adults with sort 2 diabetes and to cut back the chance of main opposed cardiovascular occasions (cardiovascular demise, non-fatal myocardial infarction or non-fatal stroke) in adults with sort 2 diabetes and established heart problems.
About Rybelsus®
Oral semaglutide is run as soon as every day and is accepted to be used in three therapeutic doses, 3 mg, 7 mg and 14 mg underneath the model title Rybelsus®. It’s indicated for the therapy of adults with insufficiently managed sort 2 diabetes mellitus to enhance glycemic management as an adjunct to weight-reduction plan and train.
About Wegovy®
As soon as-weekly subcutaneous semaglutide 2.4 mg is accepted underneath the model title Wegovy® and is indicated together with a decreased calorie weight-reduction plan and elevated bodily exercise to cut back the chance of main opposed cardiovascular occasions (cardiovascular demise, non-fatal myocardial infarction, or non-fatal stroke) in adults with established heart problems and both weight problems or obese, in addition to to cut back extra physique weight and keep weight discount long run in adults and pediatric sufferers aged 12 years and older with weight problems and in adults with obese within the presence of at the least one weight-related comorbid situation.
